PerkinElmer Appoints Vice President, Business Development
News Jan 20, 2006
PerkinElmer, Inc. has announced the appointment of Dr. Aaron Geist as Vice President, Business Development for the Company.
Dr. Geist will be responsible for developing PerkinElmer's strategic partnerships and acquisition opportunities.
Geist joins PerkinElmer from Robert W. Baird where he served as Director and Senior Research Analyst.
In this role, he was responsible for generating investor research on 22 life sciences, medical diagnostics and medical device companies, and was chosen as a top analyst by both The Wall Street Journal and Forbes/StarMine in 2004. He previously worked in medical research with a specialization in infectious diseases.
Aaron holds a Ph.D. in microbiology and molecular virology from Thomas Jefferson University in Philadelphia, Pennsylvania, and bachelor of science degrees in genetics and biology from the University of Western Ontario in Canada.
"Aaron brings exceptional domain knowledge, market understanding and business acumen to his new role," said Robert F. Friel, Vice Chairman of PerkinElmer, Inc.
"We look forward to his leadership in developing and growing the PerkinElmer business portfolio, particularly in the areas of molecular medicine, genetic screening and medical imaging."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018